AB Science Provides Update on P-II Trial Design of Masitinib for COVID-19
Shots:
- The P-II (AB20001) trial was designed to assess masitinib + isoquercetin in hospitalized patients (>18yrs.) with moderate (level 4)/severe (level 5) COVID-19; now will focus only on level 4 patients with oxygen supply <6L/min & SpO2≥92%, following a DSMB recommendation
- 1EP was improvement in the clinical status post 15 days using the WHO 7-point ordinal scale. Study was only able to enrol 95 patients out of planned 200 to assess efficacy, and further evaluation of masitinib decision
- Study showed an odds ratio of 2.4 post 15 days and 3.2, 3.2 & 3.4 at days 12, 13 & 14, respectively, during sensitivity analysis in those 95 patients. Safety profile was consistent with known profile of masitinib
Ref: AB Science | Image: AB Science
Related News:- AstraZeneca Reports the EMA’s Acceptance of MAA for Sipavibart Under Accelerated Assessment to Prevent COVID-19
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
